SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001213900-17-010833
Filing Date
2017-10-23
Accepted
2017-10-23 16:38:33
Documents
1
Period of Report
2017-10-20

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT f4101917kelly_relmada.html 4  
1 OWNERSHIP DOCUMENT f4101917kelly_relmada.xml 4 3943
  Complete submission text file 0001213900-17-010833.txt   5390
Mailing Address 275 MADISON AVENUE, SUITE 702 NEW YORK NY 10016
Business Address 275 MADISON AVENUE, SUITE 702 NEW YORK NY 10016 646-677-3853
RELMADA THERAPEUTICS, INC. (Issuer) CIK: 0001553643 (see all company filings)

IRS No.: 455401931 | State of Incorp.: NV | Fiscal Year End: 0630
SIC: 2834 Pharmaceutical Preparations

Mailing Address 300 EAST 56TH STREET, APT 19E NEW YORK, NY 10022
Business Address
Kelly Paul Edward (Reporting) CIK: 0001658544 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-55347 | Film No.: 171149274